Department of Family and Community Medicine, University of California, Davis, Sacramento, CA, USA; Center for Healthcare Policy and Research, University of California, Davis, Sacramento, CA, USA.
Department of Family and Community Medicine, University of California, Davis, Sacramento, CA, USA; Center for Healthcare Policy and Research, University of California, Davis, Sacramento, CA, USA.
Drug Alcohol Depend. 2024 May 1;258:111277. doi: 10.1016/j.drugalcdep.2024.111277. Epub 2024 Mar 30.
Health plan disenrollment may disrupt chronic or preventive care for patients prescribed long-term opioid therapy (LTOT).
To assess whether overdose events in patients prescribed LTOT are associated with subsequent health plan disenrollment.
Retrospective cohort study.
Data from the Optum Labs Data Warehouse which includes de-identified medical and pharmacy claims and enrollment records for commercial and Medicare Advantage enrollees. The database contains longitudinal health information on patients, representing a mixture of ages and geographical regions across the United States.
Adults prescribed stable opioid therapy (≥10 morphine milligram equivalents/day) for a 6-month baseline period prior to an index opioid prescription from January 1, 2018 to December 31, 2018.
Health plan disenrollment during follow-up.
The cohort comprised 404,151 patients who were followed up after 800,250 baseline periods of stable opioid dosing. During a mean follow-up of 9.1 months, unadjusted disenrollment rates among primary commercial beneficiaries and Medicare Advantage enrollees were 37.2 and 13.9 per 100 person-years, respectively. Incident overdoses were associated with subsequent health plan disenrollment with a statistically significantly stronger association among primary commercial insurance beneficiaries [adjusted incidence rate ratio (aIRR) 1.48 (95% CI: 1.33-1.64)] as compared to Medicare Advantage enrollees [aIRR 1.15 (95% CI: 1.07-1.23)].
Among patients prescribed long-term opioids, overdose events were strongly associated with subsequent health plan disenrollment, especially among primary commercial insurance beneficiaries. These findings raise concerns about the social consequences of overdose, including potential health insurance loss, which may limit patient access to care at a time of heightened vulnerability.
健康计划退保可能会打乱长期接受阿片类药物治疗(LTOT)的患者的慢性或预防性护理。
评估 LTOT 处方患者的过量事件是否与随后的健康计划退保相关。
回顾性队列研究。
来自 Optum Labs 数据仓库的数据,其中包括来自 2018 年 1 月 1 日至 2018 年 12 月 31 日的索引阿片类药物处方前 6 个月基线期内的去识别医疗和药房索赔和参保记录。该数据库包含患者的纵向健康信息,代表美国各地不同年龄和地理位置的混合人群。
在 2018 年 1 月 1 日至 2018 年 12 月 31 日期间,每位患者在指数阿片类药物处方前的 6 个月基线期内接受稳定的阿片类药物治疗(≥10 吗啡毫克当量/天)。
随访期间的健康计划退保。
该队列包括 404151 名患者,他们在 800250 个稳定阿片类药物剂量的基线期后接受了随访。在平均 9.1 个月的随访中,初级商业受益人和医疗保险优势计划参保者的未调整退保率分别为每 100 人年 37.2 和 13.9。与未发生过量事件的患者相比,发生过量事件与随后的健康计划退保相关,与初级商业保险受益者相比,这种相关性更强[调整后的发病率比(aIRR)为 1.48(95%可信区间:1.33-1.64)],而与医疗保险优势计划参保者相比[aIRR 为 1.15(95% CI:1.07-1.23)]。
在接受长期阿片类药物治疗的患者中,过量事件与随后的健康计划退保密切相关,尤其是在初级商业保险受益者中。这些发现引起了人们对过量事件的社会后果的关注,包括潜在的医疗保险损失,这可能会限制患者在脆弱时期获得护理的机会。